JANUS KINASE INHIBITOR MARKET ANALYSIS

Regional Analysis

The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation of cytokines causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic disease, which is characterized by inflammation of connective tissues such as cartilage and blood vessel lining. According to National Center for Biotechnology Information (NCBI), the highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000 person) during the period August 2013- September 2016. Therefore, high prevalence of SLE is expected to boost North America janus kinase inhibitor market growth over the forecast period.

Increasing research and development projects for launch of new drugs is expected to fuel Asia Pacific janus kinase inhibitor market growth over the forecast period. For instance, Astellas Pharma Inc. — a Japan-based pharmaceutical company — conducted Phase-3 clinical trial (study completed in November 2017) of drug Peficitinib for treatment of Rheumatoid arthritis. The study was conducted to check the superiority of Peficitinib alone and in combination with disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis who did not show sufficient response to DMARDs. Peficitinib is an inhibitor of Jak 1 and Jak that inhibits Interleukin 2 dependent T cell proliferation and STAT5 phosphorylation. These factors are expected to support global janus kinase inhibitor market growth over the forecast period.

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa